Cahill Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-1,395
Closed -$104K – 255
2021
Q3
$104K Buy
+1,395
New +$117K 0.02% 265

Other funds holding ARKG

Cahill Financial Advisors's ARKG Position: Q4 2021 in Review

Cahill Financial Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 1,395 shares — an estimated $104K sold.

Cahill Financial Advisors first reported a position in ARKG in Q3 2021 and held it in 1 quarter. The position peaked at $104K in Q3 2021. 462 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Cahill Financial Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 1,395 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $104K.
  • Cahill Financial Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's ARK Genomic Revolution ETF position peaked at $104K in Q3 2021.
  • 462 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.